Biomarker Testing for Immunotherapy

Author:
Jarushka Naidoo
Search for other papers by Jarushka Naidoo in
Current site
Google Scholar
PubMedClose
 MBBCh
Volume/Issue:
Volume 17: Issue 5.5
Online Publication Date:
May 2019
DOI:
https://doi.org/10.6004/jnccn.2019.5021
Restricted access

Immunotherapy is now the fourth pillar of cancer treatment, but the methodology used to determine who will benefit is still a work in progress. PD-L1 is commonly used as a predictive biomarker for immunotherapy, but others—such as immunogenic tumor biomarkers, host environment biomarkers and biomarkers of nonresponse—are being actively investigated. Additionally, research in combining biomarkers is currently being conducted, with new data emerging all the time.

Correspondence: Jarushka Naidoo, MBBCh, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 301 Mason Lord Drive, Suite 4500, Baltimore, MD 21224. Email: jnaidoo1@jhmi.edu
  • Collapse
  • Expand
  • 1.

    Mayeux R. Biomarkers: potential uses and limitations. NeuroRx 2004;1:182–188.

  • 2.

    Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89–95.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–2454.

  • 4.

    Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540–1550.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823–1833.

  • 6.

    Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 2015;348:124–128.

  • 7.

    Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509–2520.

  • 8.

    McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016;351:1463–1469.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer—a meta-analysis. J Thorac Oncol 2017;12:403–407.

  • 10.

    Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov 2018;8:822–835.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Bultman SJ. Emerging roles of the microbiome in cancer. Carcinogenesis 2014;35:249–255.

  • 12.

    Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018;359:97–103.

  • 13.

    Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 2016;7:10391.

Copyright:
Copyright © 2019 by the National Comprehensive Cancer Network 2019
Page Numbers:
3
Article Category:
Research Article
Print Publication Date:
01 May 2019
Online Publication Date:
May 2019
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1254 117 2
PDF Downloads 830 39 3
EPUB Downloads 0 0 0